NasdaqGS:NBIX

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Neurocrine Biosciences, Inc., a commercial-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of neurological, endocrine, and psychiatric disorders in the United States. More Details


Snowflake Analysis

Solid track record with high growth potential.


Similar Companies

Share Price & News

How has Neurocrine Biosciences's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: NBIX's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-3.3%

NBIX

-4.0%

US Biotechs

-1.4%

US Market


1 Year Return

-1.5%

NBIX

31.7%

US Biotechs

17.8%

US Market

Return vs Industry: NBIX underperformed the US Biotechs industry which returned 33.9% over the past year.

Return vs Market: NBIX underperformed the US Market which returned 18.5% over the past year.


Shareholder returns

NBIXIndustryMarket
7 Day-3.3%-4.0%-1.4%
30 Day-3.4%0.1%4.7%
90 Day-22.9%-3.5%8.2%
1 Year-1.5%-1.5%34.0%31.7%20.5%17.8%
3 Year62.6%62.6%18.7%12.8%42.2%32.7%
5 Year93.2%93.2%13.4%5.4%83.4%62.7%

Price Volatility Vs. Market

How volatile is Neurocrine Biosciences's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Neurocrine Biosciences undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: NBIX ($95.82) is trading below our estimate of fair value ($246.9)

Significantly Below Fair Value: NBIX is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: NBIX is poor value based on its PE Ratio (43.2x) compared to the US Biotechs industry average (29.6x).

PE vs Market: NBIX is poor value based on its PE Ratio (43.2x) compared to the US market (19x).


Price to Earnings Growth Ratio

PEG Ratio: NBIX is poor value based on its PEG Ratio (1.2x)


Price to Book Ratio

PB vs Industry: NBIX is overvalued based on its PB Ratio (10.7x) compared to the US Biotechs industry average (3.4x).


Next Steps

Future Growth

How is Neurocrine Biosciences forecast to perform in the next 1 to 3 years based on estimates from 21 analysts?

35.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: NBIX's forecast earnings growth (35.8% per year) is above the savings rate (2.2%).

Earnings vs Market: NBIX's earnings (35.8% per year) are forecast to grow faster than the US market (22.2% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: NBIX's revenue (18.8% per year) is forecast to grow faster than the US market (10.1% per year).

High Growth Revenue: NBIX's revenue (18.8% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: NBIX's Return on Equity is forecast to be high in 3 years time (31.2%)


Next Steps

Past Performance

How has Neurocrine Biosciences performed over the past 5 years?

49.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: NBIX has a large one-off loss of $123.1M impacting its June 30 2020 financial results.

Growing Profit Margin: NBIX's current net profit margins (20.4%) are higher than last year (3%).


Past Earnings Growth Analysis

Earnings Trend: NBIX has become profitable over the past 5 years, growing earnings by 49.5% per year.

Accelerating Growth: NBIX's earnings growth over the past year (1033.1%) exceeds its 5-year average (49.5% per year).

Earnings vs Industry: NBIX earnings growth over the past year (1033.1%) exceeded the Biotechs industry -3.2%.


Return on Equity

High ROE: NBIX's Return on Equity (24.6%) is considered high.


Next Steps

Financial Health

How is Neurocrine Biosciences's financial position?


Financial Position Analysis

Short Term Liabilities: NBIX's short term assets ($1.1B) exceed its short term liabilities ($573.0M).

Long Term Liabilities: NBIX's short term assets ($1.1B) exceed its long term liabilities ($111.4M).


Debt to Equity History and Analysis

Debt Level: NBIX's debt to equity ratio (50.5%) is considered high.

Reducing Debt: Insufficient data to determine if NBIX's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: NBIX's debt is well covered by operating cash flow (85.2%).

Interest Coverage: NBIX's interest payments on its debt are well covered by EBIT (24.8x coverage).


Balance Sheet


Next Steps

Dividend

What is Neurocrine Biosciences's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate NBIX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate NBIX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if NBIX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NBIX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of NBIX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.0yrs

Average management tenure


CEO

Kevin Gorman (62 yo)

12.75yrs

Tenure

US$9,450,826

Compensation

Dr. Kevin C. Gorman, Ph.D., has been the President and Chief Executive Officer of Neurocrine Biosciences, Inc. since January 2008. Dr. Gorman is a Founder of Neurocrine Biosciences, Inc. Dr. Gorman served ...


CEO Compensation Analysis

Compensation vs Market: Kevin's total compensation ($USD9.45M) is about average for companies of similar size in the US market ($USD7.32M).

Compensation vs Earnings: Kevin's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Kevin Gorman
CEO & Director12.75yrsUS$9.45m0.47%
$ 42.3m
Matthew Abernethy
Chief Financial Officer2.92yrsUS$5.82m0.0086%
$ 770.6k
Haig Bozigian
Chief Development Officer13.83yrsUS$4.78m0.16%
$ 14.5m
Eric Benevich
Chief Commercial Officer5.42yrsUS$5.79m0.016%
$ 1.5m
Eiry Roberts
Chief Medical Officer2.75yrsUS$4.90m0.012%
$ 1.1m
Dimitri Grigoriadis
Chief Research Officer13.75yrsUS$3.33m0.085%
$ 7.7m
Jane Sorensen
Head of Investor Relationsno datano datano data
Darin Lippoldt
Chief Legal Officer & Corporate Secretary6yrsno data0.030%
$ 2.7m
Kyle Gano
Chief Business Development and Strategy Officer9.75yrsUS$4.57m0.10%
$ 9.3m
Julie Cooke
Chief Human Resources Officer3.08yrsno data0.010%
$ 921.8k
Malcolm Lloyd-Smith
Chief Regulatory Officer6.08yrsno data0.029%
$ 2.6m
David Boyer
Chief Corporate Affairs Officer1.08yrsno datano data

6.0yrs

Average Tenure

55yo

Average Age

Experienced Management: NBIX's management team is seasoned and experienced (6 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Kevin Gorman
CEO & Director12.75yrsUS$9.45m0.47%
$ 42.3m
Richard Pops
Independent Director22.5yrsUS$531.60k0.032%
$ 2.8m
Stephen Sherwin
Independent Director21.5yrsUS$534.60k0.032%
$ 2.9m
William Rastetter
Independent Chairman of the Board9.42yrsUS$671.98k0.027%
$ 2.4m
Gary Lyons
Independent Director27.67yrsUS$507.10k0.24%
$ 21.8m
George Morrow
Independent Director5yrsUS$528.60k0%
$ 0
Shalini Sharp
Independent Director0.67yrno data0%
$ 0
Leslie Norwalk
Independent Director1.08yrsUS$804.35k0%
$ 0

11.1yrs

Average Tenure

65yo

Average Age

Experienced Board: NBIX's board of directors are seasoned and experienced ( 11.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Neurocrine Biosciences, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Neurocrine Biosciences, Inc.
  • Ticker: NBIX
  • Exchange: NasdaqGS
  • Founded: 1992
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$9.002b
  • Shares outstanding: 93.25m
  • Website: https://www.neurocrine.com

Number of Employees


Location

  • Neurocrine Biosciences, Inc.
  • 12780 El Camino Real
  • San Diego
  • California
  • 92130
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
NBIXNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDMay 1996
NB3DB (Deutsche Boerse AG)YesCommon StockDEEURMay 1996
0K6RLSE (London Stock Exchange)YesCommon StockGBUSDMay 1996
N1BI34BOVESPA (Bolsa de Valores de Sao Paulo)BDR EACH 20 REPR 1 COM NPVBRBRLOct 2020

Biography

Neurocrine Biosciences, Inc., a commercial-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of neurological, endocrine, and psychiatric disorders in the United States. ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/22 23:33
End of Day Share Price2020/10/22 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.